LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Gilde Healthcare Cooperatieve Sells 49,869 Shares of Stock

LAVA Therapeutics N.V. (NASDAQ:LVTX) major shareholder Gilde Healthcare Cooperatieve sold 49,869 shares of LAVA Therapeutics stock in a transaction on Friday, October 10th. The shares were sold at an average price of $1.55, for a total value of $77,296.95. Following the completion of the sale, the insider directly owned 5,294,178 shares of the company’s stock, valued at $8,205,975.90. The trade was a 0.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Gilde Healthcare Cooperatieve also recently made the following trade(s):

• On Thursday, October 9th, Gilde Healthcare Cooperatieve sold 48,169 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.56, for a total value of $75,143.64.
• On Wednesday, October 8th, Gilde Healthcare Cooperatieve sold 28,954 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.57, for a total value of $45,457.78.

LAVA Therapeutics Trading Down 0.6%

Shares of NASDAQ LVTX opened at $1.55 on Friday. LAVA Therapeutics N.V. has a twelve month low of $0.85 and a twelve month high of $2.09. The stock has a fifty day simple moving average of $1.55 and a 200-day simple moving average of $1.39. The stock has a market capitalization of $40.78 million, a PE ratio of -1.48 and a beta of 0.50.

LAVA Therapeutics (NASDAQ:LVTX) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). On average, equities analysts predict that LAVA Therapeutics N.V. will post -1.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of LAVA Therapeutics in a research note on Wednesday. HC Wainwright lowered their target price on LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating for the company in a research note on Tuesday, August 5th. Finally, Jefferies Financial Group cut LAVA Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $3.00 to $1.50 in a research note on Tuesday, August 5th. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $2.69.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. BML Capital Management LLC acquired a new position in shares of LAVA Therapeutics during the 1st quarter worth about $2,490,000. XTX Topco Ltd acquired a new position in shares of LAVA Therapeutics during the 1st quarter worth about $31,000. Lepercq De Neuflize Asset Management LLC acquired a new position in shares of LAVA Therapeutics during the 1st quarter worth about $29,000. Finally, Rangeley Capital LLC acquired a new position in shares of LAVA Therapeutics during the 2nd quarter worth about $36,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.